This is a routine conference update with no new data released. The next major catalyst is CHAPTER-3 topline data in Q3 2026. Monitor EAACI presentations for any incremental safety/efficacy signals, but no immediate trading action warranted.
Price Chart
Executive Summary
Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 congress, including Phase 3 RAPIDe-3 on-demand HAE data and Phase 2 CHAPTER-1 OLE prophylaxis data. The event is a routine scientific conference update with no new clinical data released today; the key catalyst remains the CHAPTER-3 topline data expected in Q3 2026.
Key Facts
- 8 abstracts accepted at EAACI 2026 (June 12-15, Istanbul), including 1 oral presentation of RAPIDe-3 Phase 3 on-demand HAE data
- 7 additional presentations cover cardiovascular safety, biomarker assay, RAPIDe-3 patient voices, and CHAPTER-1 OLE prophylaxis results
- CHAPTER-3 global pivotal Phase 3 study of deucrictibant XR for HAE prophylaxis ongoing; topline data expected Q3 2026
- CREAATE Phase 3 study for AAE-C1INH (prophylactic and on-demand) also ongoing
- No new clinical data or regulatory milestones announced in this press release
Financial Impact
No financial data disclosed; event is a scientific conference update with no revenue or cost implications
Risk Factors
- No new clinical data released today; market may be disappointed by lack of material update
- CHAPTER-3 topline data in Q3 2026 is binary risk for the stock
- Competitive landscape includes existing injectable HAE therapies (Takhzyro, Firazyr) and oral competitors (Orladeyo)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303489 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access